Monoprost (Latanoprost)

Latanoprost, the active ingredient in Monoprost, is a prostaglandin analog presented as eye drops for ocular use. It lowers intra‑ocular pressure and is indicated for open‑angle glaucoma and ocular hypertension in adults.

GNH USA supplies Monoprost as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Monoprost is a prostaglandin analog used to manage conditions that involve elevated intra‑ocular pressure. - Open‑angle glaucoma: reduces eye pressure to slow optic nerve damage. - Ocular hypertension: lowers pressure to prevent progression to glaucoma. - Elevated intra‑ocular pressure (any cause): helps maintain normal pressure levels.

Monoprost may cause a range of ocular reactions.

Common Side Effects: - Eye redness: mild conjunctival hyperemia. - Increased eyelash growth: longer, thicker lashes. - Iris pigmentation change: gradual darkening of eye colour. - Eye irritation or foreign‑body sensation. - Blurred vision shortly after instillation. - Dry eye sensation.

Serious or Rare Side Effects: - Severe eye inflammation (uveitis or iritis). - Allergic reaction: swelling, itching, or rash. - Sudden loss of vision. - Persistent eye pain. - Corneal edema. - Unusual changes in visual acuity.

Before using Monoprost, consider the following safety points. - Pregnancy: safety unknown; use only if benefits outweigh risks. - Breastfeeding: unknown excretion; caution advised. - Active ocular infection: contraindicated until resolved. - Monitor intra‑ocular pressure: assess response after initiation. - Contact lens wear: avoid using lenses for at least 15 minutes after instillation. - Store at room temperature: keep in original container, protect from light and moisture.

Monoprost can interact with other ophthalmic agents and systemic medications.

Major Interactions (Avoid): - Concurrent use of other prostaglandin analog eye drops: additive pressure‑lowering effect may cause hypotony. - Non‑steroidal anti‑inflammatory eye drops: may diminish latanoprost efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blocker eye drops: combined use may lead to excessive IOP reduction. - Carbonic anhydrase inhibitor eye drops: increased overall pressure‑lowering effect. - Systemic carbonic anhydrase inhibitors (e.g., acetazolamide): monitor for enhanced IOP decrease.